Work

722 - Efficacy of povorcitinib for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 subgroup analysis from a randomized, placebo-controlled, phase 2b clinical trial

Year: 2024

Type: article

Source: British Journal of Dermatology

DOI: 10.1093/bjd/ljae266.095

Authors: Amit G Pandya, Thierry Passeron, Andrew Blauvelt, Nanja van Geel, Kurt Brown, Lois Erskine, Zhenyi Xue, Khaled Ezzedine

Institutions: Palo Alto Medical Foundation, The University of Texas Southwestern Medical Center, Inserm, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Centre Méditerranéen de Médecine Moléculaire, Oregon Medical Research Center, Ghent University Hospital, Incyte (United States), Université Paris-Est Créteil, Hôpitaux Universitaires Henri-Mondor

Language: English

Topic: melanin and skin pigmentation

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401436030

FWCI: 0.384

Cites:

Cited by: 2

Related to: 10